Closed for Enrollment

• A Phase 3, Multicenter, Open-label, Randomized Study Of SGI-110 Versus Treatment Choice (TC) In Adults With Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates For Intensive Remission Induction Chemotherapy Scottsdale/Phoenix, AZ Rochester, MN

  To compare efficacy and safety between SGI-110 and Treatment Choice in adults with previously untreated AML who are not considered candidates for intensive remission induction chemotherapy.

• A Phase1-2 Pharmacokinetic Guided Dose-Escalation And Dose-Confirmation Study Of ASTX727, A Combination Of The Oral Cytidine Deaminase Inhibitor (CDAi) E7727 With Oral Decitabine In Subjects With Myelodysplastic Syndromes (MDS) Scottsdale/Phoenix, AZ

  This 2-stage, open-label study will evaluate safety and pharmacokinetics of ASTX727, as well as determine the dose for the study's second stage. In the second stage the selected dose will be confirmed and evaluated for clinical activity, including response rate.